AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy

Table 3

Active clinical trial protocols evaluating hematopoietic stem cell transplant in ARL.

Study identifier	Phase	Study	Start date	Primary endpoint
NCT00345865	II	Cyclophosphamide + TBI versus carmustine, cyclophosphamide and etoposide conditioning followed by ASCT in AIDS-related NHL or HL	November 2005	DFS and OS
NCT00641381	II	Carmustine, Etoposide, Cyclophosphamide and ASCT in ARL	March 2000	Feasibility and toxicity
NCT00858793	I/II	HDT and transplantation of gene-modified ASCT for high-risk ARL	October 2008	Adverse events
NCT00968630	II	Immune response after HSCT in HIV-positive patients with hematologic cancer	August 2009	HIV-specific immune response
NCT01045889	II	R-CHOP followed by HDT and ASCT	January 2007	OS
NCT01141712  (AMC 071)	II	HDT (BEAM) and ASCT in ARL	February 2011	OS
NCT01410344	II	Allogeneic HSCT for hematological cancers and myelodysplastic syndromes in HIV-infected individuals	September 2011	NRM

TBI: total body irradiation; NHL: non-Hodgkin’s lymphoma; HL: Hodgkin’s lymphoma; DFS: disease-free survival; OS: overall survival; HDT: high-dose therapy; ASCT: autologous stem cell transplant; HSCT: hematopoietic stem cell transplant; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; BEAM: carmustine, etoposide, cytarabine, melphalan; NRM: nonrelapse mortality.
Source: http://clinicaltrials.gov/.